Trader: Low Volume ...
Health Care: Drugs
Arqule Inc. (ARQL: NASDAQ)
$5.68 0.15 | 2.71%
06/04/12 - 04:00 PM ET
Company Balance Sheet
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 11.10M | 20.46M | 36.55M | 141.89M |
| Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 72.19M | 81.81M | 157.15M | 142.66M |
| Property, Plant & Equipment, Gross | 22.14M | 21.55M | 21.19M | 20.53M |
| Accumulated Depreciation & Depletion | 19.20M | 18.03M | 16.60M | 14.91M |
| Property, Plant & Equipment, Net | 2.94M | 3.52M | 4.58M | 5.62M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 41.92M | 3.54M | 10.14M | 65.93M |
| Total Non-Current Assets | 44.86M | 7.05M | 14.73M | 71.55M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 117.05M | 88.87M | 171.88M | 214.21M |
| Accounts Payable | 226.00K | 1.26M | 8.37M | 495.00K |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 552.00K |
| Total Current Liabilities | 48.89M | 46.91M | 83.58M | 82.98M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 38.43M | 56.52M | 76.76M | 87.76M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 38.43M | 56.52M | 76.76M | 87.76M |
| Total Liabilities | 87.32M | 103.43M | 160.34M | 170.74M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 29.73M | -14.56M | 11.54M | 43.47M |
| Common Par | 538.00K | 450.00K | 448.00K | 442.00K |
| Additional Paid In Capital | 438.68M | 383.71M | 379.62M | 375.48M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -409.48M | -398.72M | -368.59M | -332.45M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | -6.00K | -7.00K | 55.00K | 0.00 |
| Total Capitalization | 29.73M | -14.56M | 11.54M | 43.47M |
| Total Equity | 29.73M | -14.56M | 11.54M | 43.47M |
| Total Liabilities & Stock Equity | 117.05M | 88.87M | 171.88M | 214.21M |
| Total Common Shares Outstanding | 53.83M | 44.97M | 44.77M | 44.15M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 52.78M | 44.53M | 44.17M | 43.87M |
| Diluted Weighted Shares Outstanding | 52.78M | 44.53M | 44.17M | 43.87M |
| Number of Employees | 103 | 115 | 111 | 107 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with ARQL
- Portfolio NameUser Type
- Contributor22 Biopharma Stocks With Br...
- UserGFNN Stockdiagnostics 11
- ContributorStocks Under-$10 Moving Hig...
- Contributor7 Cancer Drug Stocks to Kno...
- UserASCO 2010
- UserDano Boy's List
- User2bullmates Portfolio 1
- UserASCO 2009 Part 2 the end of...
- UserBVF Inc.
- UserASCO is coming...Papers rel...
Latest ARQL Headlines from TheStreet
- ASCO 2012 Live Blog -- Saturday 06.02.12 | 07:06 am
- 22 Biopharma Stocks With Breakout Potential in 2012 05.22.12 | 08:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) 05.17.12 | 06:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus 05.16.12 | 06:05 pm
- 3 Stocks Under $10 Moving Higher 04.03.12 | 12:04 pm
- 7 Cancer Drug Stocks to Know Right Now 03.14.12 | 09:03 am
- Arqule Inc. Stock Downgraded (ARQL) 11.15.11 | 06:11 am
- Arqule Inc. Stock Upgraded (ARQL) 05.10.11 | 07:05 am
- Stocks Under $10: Soaring Biotech Stock
01.19.11 | 08:01 am - Crystallex International, Sprint Nextel: Early Volume Plays 06.07.10 | 08:06 am
Press Releases for ARQL
- Positive Phase 2 Study Results For Tivantinib In Previously Treated Hepatocellular Carcinoma To Be Presented At ASCO - Business Wire 06.02.12 | 07:06 am
- ArQule, Inc. To Present At Jefferies 2012 Global Healthcare Conferences - Business Wire 05.31.12 | 08:05 am
- ArQule And Daiichi Sankyo Announce Completion Of Patient Recruitment In Phase 3 Clinical Trial Of Tivantinib In Non-Small Cell Lung Cancer - Business Wire 05.18.12 | 07:05 am
- Positive Phase 2 Clinical Data With Tivantinib In Hepatocellular Carcinoma To Be Highlighted In Oral Presentation At 2012 Annual Meeting Of American Society Of Clinical Oncology - Business Wire 05.17.12 | 07:05 am
- ArQule Reports First Quarter 2012 Financial Results - Business Wire 05.03.12 | 07:05 am
- ArQule To Report First Quarter 2012 Financial Results On May 3, 2012 - Business Wire 04.26.12 | 08:04 am
- ArQule Announces Completion Of Common Stock Offering With Full Exercise Of Option To Purchase Additional Shares - Business Wire 04.16.12 | 04:04 pm
- ArQule Prices Public Offering Of Common Stock - Business Wire 04.11.12 | 07:04 am
- ArQule Announces Proposed Public Offering - Business Wire 04.10.12 | 07:04 am
- ArQule Announces Presentations At AACR 102nd Annual Meeting - Business Wire 03.29.12 | 08:03 am
Partner Headlines for ARQL
- Stock Insights: Dendreon, Medtronic, FedEx, ArQule, Rentrak June 4th - Wall St. Cheat Sheet 06.04.12 | 10:06 am
- ArQule Announces Positive Phase 2 Study Results for Tivantinib in Previously Treated Hepatocellular Carcinoma - Benzinga 06.02.12 | 06:06 pm
- Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 3 - Seeking Alpha 05.25.12 | 08:05 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 05.01.12 | 09:05 am
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 04.02.12 | 09:04 am
- Company News for January 18, 2012 - Corporate Summary - Zacks 01.18.12 | 10:01 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 11.15.11 | 09:11 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 10.04.11 | 09:10 am
- Drugs to Watch at ASCO 2011 - Seeking Alpha 06.02.11 | 08:06 am
- Future Biotech Superstars - Seeking Alpha 03.30.11 | 09:03 am
